GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Business & Industry
- Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
- AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
- Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
- Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
- Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
Research & Development
- New evidence COVID-19 antibodies, vaccines less effective against variants
- Vaccine development software shows promise in influenza effort, could help defeat coronavirus
- Researchers discover SARS-CoV-2 inhibitors
- Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
- First COVID-19 COVAX vaccine doses administered in Africa
- Assessing a compound's activity, not just its structure, could accelerate drug discovery
- Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients
Conferences & Events
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
Regulatory Affairs
- FDA issues Emergency Use Authorization for third COVID-19 vaccine
- FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
- EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
- FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
- Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application